Stable Istotope Labelled Reslizumab Biosimilar – Anti-IL5 mAb – Research Grade
Size | |
---|---|
Brand | |
Product type | |
Clonality | |
Expression system | |
Applications |
Product name | Stable Istotope Labelled Reslizumab Biosimilar - Anti-IL5 mAb - Research Grade |
---|---|
Source | CAS 241473-69-8 |
Species | Humanized |
Expression system | Mammalian cells |
Purity | >95% |
Buffer | PBS buffer PH7.5 |
Delivery condition | Blue Ice |
Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
Storage condition | store at -80°C |
Brand | ProteoGenix |
Aliases /Synonyms | CDP-835,JES1-39D10,SCH55700 |
Reference | PX-TA1198-SIL |
Related Products | PX-P4558 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | IgG4-nd |
Clonality | Monoclonal Antibody |
Format | Lyophilized |
Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
Isotopic Enrichment | 99% |
Stability | 1 year |
General information on Anti-IL5(Homo sapiens) (Reslizumab) Monoclonal Antibody
Reslizumab is a humanized interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), produced by recombinant DNA technology in murine non-secretory myeloma 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophil markers. Elevated levels of eosinophils increase the risk of exacerbation of asthma, including allergic and non-allergic forms of asthma characterized by eosinophilia. By targeting IL-5 and disrupting its signaling pathway, reslizumab aims to inhibit the maturation of eosinophils and promote programmed cell death. Reslizumab is sold as Cinqaero in Europe.
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Reviews
There are no reviews yet.